Denali Capital Reports Q1 2025 Loss Amid Merger Plans and Financial Challenges

Denali Capital Acquisition Corp. (NASDAQ: DECAW) recently released its quarterly report for the period ending March 31, 2025, marking significant developments in its financial status and operational trajectory. Below are the key highlights and statistics extracted from the report.

Recent Developments:

• Posted a net loss of $194,603 for Q1 2025 compared to a net income of $264,330 for the same period in 2024.
• Total assets as of March 31, 2025, amounted to $9,147,903, a slight increase from $9,037,873 at the end of 2024.
• Cash on hand decreased to $2,736 from $16,868 as of December 31, 2024.
• Investment held in the Trust Account now stands at $9,145,167, up from $9,021,005 in the previous reporting period.
• Failure to regain compliance with Nasdaq listing rules resulted in the delisting of the Company's securities on April 16, 2025.

Positive Aspects:

• Reduction in formation and operating costs to $246,600 in Q1 2025 from $368,252 in Q1 2024, indicating improved cost management.
• Generated income of $78,971 from investments held in the Trust Account.
• The company has obtained financial backing through multiple convertible promissory notes, securing further liquidity for its operations.

Negative Aspects:

• Significant net loss for the quarter, reflecting ongoing challenges in achieving operational revenues.
• Accumulated deficit increased to $(10,736,738) as of March 31, 2025, from $(10,417,973) at the end of 2024.
• Potential liquidity issues, as the working capital deficit stands at $(7,848,981).
• Absence of business operations until a business combination is completed, which poses inherent risks and uncertainties.

Statistical Overview:

• Basic and diluted net income per redeemable ordinary share for Q1 2025: $0.07, down from $0.10 in Q1 2024.
• Basic and diluted net loss per non-redeemable ordinary share for Q1 2025: $(0.10), an increase from $(0.08) in Q1 2024.
• Total liabilities grew to $10,739,217, reflecting financial obligations that the company must manage moving forward.
• From the total authorized shares, 510,000 Class A ordinary shares are issued and outstanding, with 751,837 shares redeemable as of March 31, 2025.

The upcoming merger with Semnur Pharmaceuticals marks a crucial turning point, with a combined equity value targeted at $2.5 billion. The management team is optimistic but aware of the challenges that lie ahead in ensuring the business combination proceeds as planned, especially in light of current liquidity conditions.